Haemonetics (NYSE:HAE) announced today that it appointed Roy Galvin as president of its global plasma and blood center.
Galvin’s position becomes effective Oct. 10, 2022. He will report to Haemonetics President and CEO Chris Simon.
His responsibilities in the role include driving growth objectives and advancing the company’s leadership positions and innovation, according to a news release. He will oversee the delivery of collectors’ critical needs while supporting global demand for plasma-derived therapies.
Galvin’s role also includes the development of strategies to leverage Haemonetics’ global footprint. He will help to expand in the non-commercial plasma market through blood component collection.
“Haemonetics has long been the established leader in the plasma and blood collection markets for solutions that make a meaningful difference for customers and the donors they serve,” said Galvin. “I look forward to helping the company continue to distinguish itself for best-in-class products, a commitment to innovation and superior customer service and support.”
An industry veteran
Before joining Haemonetics, Galvin spent more than 25 years at Medtronic. His leadership roles at the medtech giant included SVP, commercial for U.S. cranial and spinal technologies. He also serves as SVP, commercial, Americas for Medtronic’s restorative therapy group.
Galvin held the role of VP, U.S. sales for surgical technologies. He also served as director of global marketing for neurologic technologies. Before Medtronic, Galvin held positions at Xomed ENT, Corin Orthopedics, Biomet and Zimmer Orthopedic.
“We are pleased to add Roy’s vast experience at such an exciting time in our growth,” said Simon. “As plasma volumes continue to recover and the industry strives to replenish supplies of life-saving medicines, Haemonetics is standing apart for providing the only fully-integrated solution addressing all of collectors’ most pressing needs, improving productivity and throughput and lowering costs to collect.
“We also continue to help blood centers across the globe collect the blood components in the greatest demand, and attract and retain the right donors. We welcome Roy’s leadership to help drive significant long-term results for our plasma and blood center businesses.”